How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

910 results for

Rivastigmine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

901. Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. (PubMed)

Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. Rivastigmine has demonstrated significant benefits in patients with mild to moderate Alzheimer's disease (AD). We aimed to confirm whether rivastigmine was effective in patients with or without concurrent vascular risk factors (VRF), as previously suggested. We chose to stratify the 725 patients involved in an international dose-ranging study according to the presence of arterial hypertension (a marker of VRF (...) ) at baseline. Efficacy in each subgroup was assessed using the ADAS-cog, a measure of cognitive performance, the Progressive Deterioration Scale (PDS) and the Clinician's Interview-Based Impression of Change (CIBIC) with caregiver input. Patients receiving rivastigmine 6-12 mg/day showed better outcomes on the ADAS-cog than those receiving placebo, in both the hypertensive and non-hypertensive subgroups. Hypertensive patients receiving rivastigmine 6-12 mg/day also showed improvement over those receiving 1

2002 International journal of clinical practice

902. Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. (PubMed)

Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. To investigate the bioavailability of rivastigmine, an approved therapy for patients with mild to moderate dementia of the Alzheimer's type, at the highest approved single dose of 6 mg.Randomised, two-period crossover, single-centre, non-blinded, inpatient study.Eleven patients (five females and six males) with mean age 69.5 years.The 6 mg oral dose was compared (...) with a 2 mg intravenous dose of rivastigmine infused over a 1-hour period. Plasma concentrations of rivastigmine and its metabolite NAP 226-90 were measured with a gas chromatographic/mass spectrometric method.Following oral administration of a single 6 mg capsule, rivastigmine is rapidly absorbed with an average time to peak plasma concentration of about 1 hour and an average peak concentration of about 25.6 g/L. By a noncompartmental approach, the absolute bioavailability of the 6 mg oral dose

2002 Clinical pharmacokinetics

903. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. (PubMed)

A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. This 12-week, multinational study compared the tolerability and cognitive effects of donepezil (up to 10 mg once daily) and rivastigmine (up to 6 mg twice daily) in 111 patients with mild to moderate Alzheimer's disease. Both medications were administered open label according to recommended dosing regimens from the respective product labelling available (...) during the conduct of the study. More patients in the donepezil group (89.3%) completed the study compared with the rivastigmine group (69.1%; p=0.009), and 10.7% of the donepezil group and 21.8% of the rivastigmine group discontinued due to adverse events (AEs); 87.5% of donepezil-treated patients and 47.3% of rivastigmine-treated patients remained on the maximum approved dose of each drug at the last study visit. Both groups showed comparable improvements on the ADAS-cog administered by raters

2002 International journal of clinical practice

904. Electrocardiographic effects of rivastigmine. (PubMed)

Electrocardiographic effects of rivastigmine. The electrocardiographic (ECG) effects of rivastigmine treatment were assessed in mild to moderately severe Alzheimer's disease (AD) by analysis of four 26-week, double-blind, multicenter, placebo-controlled, phase III clinical trials. Of an initial 2791 patients, 77% completed treatment. Seventy-one percent required at least one concomitant medication for conditions other than AD, with 34% requiring cardiovascular medications. Safety assessments (...) included ECGs, adverse events, vital signs, and clinical laboratory parameters. Pooled 12-lead ECG data were analyzed by an independent cardiologist blinded to treatment group and clinical information. Heart rate, PR, QRS, and QTc intervals did not differ significantly between treatment and placebo groups. Percentage change from baseline for PR, QRS, and QTc intervals was also no different. In conclusion, rivastigmine appears not to produce adverse effects on cardiac function assessed by ECG.

2002 Journal of clinical pharmacology

905. Rivastigmine for Alzheimer's Disease: Improvement Versus Reduced Worsening. (PubMed)

Rivastigmine for Alzheimer's Disease: Improvement Versus Reduced Worsening. BACKGROUND: Alzheimer's disease (AD) is the most common cause of dementia in later life. It is manifested by gradual and progressive decline in cognitive function and ability to perform activities of daily living (ADL) and the development of behavioral disturbances. Progressive reduction in functional ability reduces independence and quality of life and adversely affects caregivers and society. Therefore, benefit from (...) any AD therapy may be obtained not only from improved function but also from stabilization or reduced worsening of function. METHOD: This retrospective study of pooled data from 3 randomized, placebo-controlled trials (N = 2126) compared the incidence of different levels of worsening between 2 rivastigmine treatment groups and a placebo group at week 26 for cognition, using the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog); global functioning, using the Clinicians' Interview

Full Text available with Trip Pro

2000 Primary care companion to the Journal of clinical psychiatry

906. Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease. (PubMed)

Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease. Rivastigmine enhances cholinergic activity and has been shown in clinical trials to decrease the rate of deterioration in Alzheimer's disease. It remains unclear where in the brain it exerts its effect. Functional magnetic resonance imaging (fMRI) can be used to measure changes in brain function and relate these to cognition.To use fMRI to study brain activation with rivastigmine (...) treatment.The effect on brain activation of a single dose of rivastigmine was tested in seven patients with mild Alzheimer's disease using fMRI during face encoding, and in five patients during a parametric working memory task.During face encoding, rivastigmine increased bilateral activation in the fusiform gyrus. Brain activation was also enhanced in the prefrontal cortex in a simple working memory task. When working memory load was further increased, not only was increased activation seen, but in certain

Full Text available with Trip Pro

2002 Neurosurgery and Psychiatry

907. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. (PubMed)

Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. To study the long-term dual inhibitory effects of rivastigmine on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) in patients with AD.Eleven patients with mild AD received rivastigmine for 12 months. Cholinesterase (ChE) activities in the CSF and plasma were assessed colorimetrically. Immunoblot analysis was used to evaluate AChE isoforms. Neuropsychiatric tests were performed throughout (...) the study.At 12 months, the mean dose of rivastigmine was 8.6 mg/d and specific activities of ChE in the CSF were lower than baseline values (by 36% for AChE and 45% for BuChE), correlating with parallel reductions in the plasma (27% for AChE and 33% for BuChE). The reduction of specific activities in the CSF, but not in the plasma, appeared to be dependent on the dose and duration of treatment. Scores of some of the neuropsychological tests associated with memory and attention were correlated with both

2002 Neurology

908. Effectiveness of rivastigmine in Alzheimer’s disease : Improvements in functional ability remain unestablished (PubMed)

Effectiveness of rivastigmine in Alzheimer’s disease : Improvements in functional ability remain unestablished 10473490 1999 10 14 2018 11 13 0959-8138 319 7210 1999 Sep 04 BMJ (Clinical research ed.) BMJ Effectiveness of rivastigmine in Alzheimer's disease. Improvements in functional ability remain unestablished. 640-1 Bentham P P Gray R R Sellwood E E Raftery J J eng Comment Letter England BMJ 8900488 0959-8138 0 Carbamates 0 Cholinesterase Inhibitors 0 Phenylcarbamates PKI06M3IW0 (...) Rivastigmine AIM IM BMJ. 1999 Mar 6;318(7184):633-8 10066203 BMJ. 2000 Feb 19;320(7233):511-2 10678874 Alzheimer Disease drug therapy Carbamates therapeutic use Cholinesterase Inhibitors therapeutic use Humans Phenylcarbamates Rivastigmine Treatment Outcome 1999 9 3 1999 9 3 0 1 1999 9 3 0 0 ppublish 10473490 PMC1116501 Alzheimer Dis Assoc Disord. 1998 Dec;12(4):266-80 9876955 Seizure. 1999 Feb;8(1):8-13 10091841 Clin Ther. 1989 Jul-Aug;11(4):545-54 2776169 JAMA. 1994 Apr 6;271(13):985-91 8139083 BMJ. 1999

Full Text available with Trip Pro

1999 BMJ : British Medical Journal

909. Effectiveness of rivastigmine in Alzheimer's disease : Participation in trials should be based on clinical uncertainty, not enforcement (PubMed)

Effectiveness of rivastigmine in Alzheimer's disease : Participation in trials should be based on clinical uncertainty, not enforcement 10678874 2000 03 16 2018 11 13 0959-8138 320 7233 2000 Feb 19 BMJ (Clinical research ed.) BMJ Effectiveness of rivastigmine in Alzheimer's disease. Participation in trials should be based on clinical uncertainty, not enforcement. 511-2 Bullock R R Passmore P P Wilkinson D D Howard R R Jones R R eng Comment Letter England BMJ 8900488 0959-8138 0 Carbamates 0 (...) Neuroprotective Agents 0 Phenylcarbamates PKI06M3IW0 Rivastigmine AIM IM BMJ. 1998 Mar 7;316(7133):762-4 9529416 BMJ. 1999 Sep 4;319(7210):640-1 10473490 Alzheimer Disease drug therapy Carbamates therapeutic use Clinical Trials as Topic Humans Neuroprotective Agents therapeutic use Patient Selection Phenylcarbamates Rivastigmine 2000 3 4 9 0 2000 3 18 9 0 2000 3 4 9 0 ppublish 10678874 PMC1127540 J Gerontol. 1994 Sep;49(5):M216-22 8056940 BMJ. 1998 Mar 7;316(7133):762-4 9529416 Int J Geriatr Psychiatry. 2000

Full Text available with Trip Pro

2000 BMJ : British Medical Journal

910. Rivastigmine may improve functioning in mild to moderate Alzheimer’s disease (PubMed)

Rivastigmine may improve functioning in mild to moderate Alzheimer’s disease 10066238 1999 04 09 1756-1833 318 7184 1999 Mar 06 BMJ (Clinical research ed.) BMJ Rivastigmine may improve functioning in mild to moderate Alzheimer's disease C eng Journal Article England BMJ 8900488 0959-8138 1999 3 5 3 3 1999 3 5 3 3 1999 3 5 3 3 ppublish 10066238 PMC1115064

Full Text available with Trip Pro

1999 BMJ : British Medical Journal

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>